A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma (Q34443422)

2 August 2017

title

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma (English)

1 reference

2 August 2017

Sant P Chawla

1

1 reference

2 August 2017

Victoria S Chua

2

1 reference

2 August 2017

Andrew F Hendifar

3

1 reference

2 August 2017

Doris V Quon

4

1 reference

2 August 2017

Neelesh Soman

5

1 reference

2 August 2017

Kamalesh K Sankhala

6

1 reference

2 August 2017

D Scott Wieland

7

1 reference

2 August 2017

Daniel J Levitt

8

1 reference

2 August 2017

language of work or name

English

0 references

publication date

13 October 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

121

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

570-579

1 reference

Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Dose response evaluation of adriamycin in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

7 January 2021

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

7 January 2021

Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

7 January 2021

Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29081

7 January 2021

Identifiers

DOI

10.1002/CNCR.29081

1 reference

2 August 2017

1 reference